Literature DB >> 15542189

Cationic microparticles are a potent delivery system for a HCV DNA vaccine.

Derek T O'Hagan1, Manmohan Singh, Christine Dong, Mildred Ugozzoli, Kim Berger, Edward Glazer, Mark Selby, Mark Wininger, Philip Ng, Kevin Crawford, Xavier Paliard, Steven Coates, Michael Houghton.   

Abstract

We initially evaluated in mice the ability of naked DNA encoding intracellular forms of the E1E2 envelope proteins from HCV to induce antibody responses and compared the responses induced with the same plasmid adsorbed onto cationic poly (lactide co-glycolide) (PLG) microparticles. Although naked DNA was only able to induce detectable responses at the 100 microg dose level, making this approach impractical for evaluation in larger animals, PLG/DNA induced detectable responses at 10 microg. In addition, the PLG/DNA microparticles induced significantly enhanced responses to naked DNA when compared at the same dose level. Remarkably, PLG/DNA induced comparable responses to recombinant E1E2 protein adjuvanted with the emulsion MF59. Furthermore, PLG/DNA effectively primed for a booster response with protein immunization, while naked DNA did not. Therefore, PLG/DNA was selected for further evaluation in a non-human primate model. In a study in rhesus macaques, PLG/DNA induced seroconversion in 3/3 animals following three immunizations. Although the antibody responses appeared lower than those induced with recombinant protein adjuvanted with MF59, following a fourth dose, PLG/DNA and protein induced comparable responses. However, a single booster dose of recombinant protein administered to the animals previously immunized with PLG/DNA induced much higher responses. In addition, one of three animals immunized with PLG/DNA showed a cytotoxic T lymphocyte response in peripheral blood lymphocytes. In conclusion, cationic PLG microparticles with adsorbed HCV DNA generates potent immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542189     DOI: 10.1016/j.vaccine.2004.06.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments.

Authors:  Philip Wintermeyer; Jack R Wands
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

Review 2.  Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases.

Authors:  Azam Bolhassani; Shabnam Javanzad; Tayebeh Saleh; Mehrdad Hashemi; Mohammad Reza Aghasadeghi; Seyed Mehdi Sadat
Journal:  Hum Vaccin Immunother       Date:  2013-10-15       Impact factor: 3.452

3.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant.

Authors:  Anna U Bielinska; Paul E Makidon; Katarzyna W Janczak; Luz P Blanco; Benjamin Swanson; Douglas M Smith; Tiffany Pham; Zsuzsanna Szabo; Jolanta F Kukowska-Latallo; James R Baker
Journal:  J Immunol       Date:  2014-02-14       Impact factor: 5.422

Review 5.  Targeted immunomodulation using antigen-conjugated nanoparticles.

Authors:  Derrick P McCarthy; Zoe N Hunter; Bryce Chackerian; Lonnie D Shea; Stephen D Miller
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-03-10

Review 6.  Dendritic cell-based immunity and vaccination against hepatitis C virus infection.

Authors:  Yun Zhou; Ying Zhang; Zhiqiang Yao; Jonathan Patrick Moorman; Zhansheng Jia
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

7.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

Review 8.  A new insight into hepatitis C vaccine development.

Authors:  Chun I Yu; Bor-Luen Chiang
Journal:  J Biomed Biotechnol       Date:  2010-06-13

9.  Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5.

Authors:  Yinling Lin; Taewoo Kwon; John Polo; Yi-Fei Zhu; Stephen Coates; Kevin Crawford; Christine Dong; Mark Wininger; John Hall; Mark Selby; Doris Coit; Angelica Medina-Selby; Colin McCoin; Philip Ng; Debbie Drane; David Chien; Jang Han; Michael Vajdy; Michael Houghton
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

10.  Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA.

Authors:  Ashwin Basarkar; Dilip Devineni; Ravi Palaniappan; Jagdish Singh
Journal:  Int J Pharm       Date:  2007-05-18       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.